Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

BIO Joins Partners for Healthy Dialogues

Jim Greenwood

The Biotechnology Industry Organization (BIO) recently joined the Partners for Healthy Dialogues effort. Dialogues+ had the opportunity to ask Jim Greenwood, President and CEO of BIO, about why BIO joined the effort, the importance of collaboration and preparing for the Physician Payments Sunshine Act. “BIO and our members support transparency in the life science industry and in the relationships between industry and physicians. We also strongly believe in the value of such relationships for the Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Crowdfunding in Health Care and Biotechnology

JobsAct_photo_115x76

Smaller private companies are constantly in search of capital, but many find it difficult to navigate the step between a “friends and family” round or one with angels and an initial venture round. Crowdfunding has been used in a limited number of examples for life sciences companies, but where is this pathway heading? How should a company look at opportunities for crowdfunding? During the 12th annual BIO Investor Forum, a CEO moderator, Nicholas Franano of Novita Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

David Thomas

With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market. Is it a bubble? David Thomas, director of Industry Research and Analysis at BIO took up these questions during the opening plenary lunch of the 12th Annual BIO Investor Forum. What’s his short answer? Not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Medicare Part B: Barriers to Cancer Treatment

Davenport-Ennis

The National Patient Advocate Foundation (PAF) has seen a notable rise in calls for assistance from both Medicare beneficiaries and cancer doctors regarding difficulty accessing certain cancer drugs in the physician office setting, where most patients receive their care. As a result, patients are being forced to seek cancer treatment in the hospital setting to access their life-saving cancer medicines; this displacement disrupts their continuum of care, is inconvenient, and is more costly to the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How to Drive International Innovation: Scientific American Worldview

Worldview Super Session

Which countries are winning the innovation game? Will the U.S. maintain its leadership position in the future? Have emerging markets lived up to the hype? Which new partnerships are transforming industries? For the fifth year, Scientific American (SA) released their Worldview: A Global Biotechnology Perspective report at the 2013 BIO International Convention in Chicago. Included in this year’s report is the longest list of country rankings that SA has ever compiled and the numbers reveal Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,